Clarivate Resets 2026 Outlook Post-Divestiture, Guides FY2027 FCF to $350M-$400M
CLVT is trading near its 52-week low of $1.42 (9.9% above the low).
Summary
Clarivate reported Q3 continuing-operations revenue of $481.6M (down 9.2%) and a $80.8M net loss, then reset 2026 guidance for the post-divestiture business and introduced a 2027 view of $350M-$400M free cash flow with leverage falling to ~3.5-3.6x.
Key Events · Earnings and Guidance · CLVT
-
Q3 Revenue Falls 9.2% on Disposals
Continuing-operations revenue was $481.6M versus $530.3M a year ago, almost entirely inorganic; organic revenue still grew 0.4% and organic ACV 1.8%.
-
Net Loss Widens on Impairment
Net loss was $80.8M, or $0.13 per diluted share, driven by a $62.2M non-cash LS&H goodwill impairment; adjusted EPS rose to $0.21 from $0.18.
-
2026 Guidance Reset Post-Divestiture
Full-year outlook is now revenue of $1.965B-$1.985B, Adjusted EBITDA of $865M-$885M, adjusted EPS of $0.73-$0.77 and free cash flow of $320M-$340M, all excluding LS&H.
-
First FY2027 View: Leverage to ~3.5-3.6x
Management guided 2027 free cash flow of $350M-$400M and net leverage of ~3.5-3.6x versus ~4x today, with organic ACV growth of ~2%.
Analysis · CLVT · Technology
The headline numbers look messy: continuing-operations revenue of $481.6M fell 9.2% and the net loss widened to $80.8M on a $62.2M non-cash LS&H goodwill impairment. But the real story is the reset baseline. With Life Sciences & Healthcare now sold (closed October 6, net cash proceeds $488.4M), management re-based full-year 2026 to $1.965B-$1.985B of revenue, $865M-$885M of Adjusted EBITDA and $0.73-$0.77 of adjusted EPS. For the first time it also gave a 2027 view: $350M-$400M of free cash flow and net leverage down to ~3.5-3.6x from ~4x. Organic recurring revenue grew 1.3% and organic ACV 1.8%, so the shrinking topline reflects disposals, not collapsing demand. The plan to retire another ~$575-600M of 2028 and 2029 notes with divestiture proceeds is the concrete deleveraging step; the risk is that free cash flow guidance was cut to $320M-$340M on deal-closing timing and one-time costs.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLVT was trading at $1.56 on NYSE in the Technology sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.42 to $3.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.